Celgene Corporation (NASDAQ: CELG) today announced primary endpoint findings and updated results of secondary endpoints from the phase II international ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Notable Call Buying Activity Continues in Celgene (CELG) Following Reported Acquisition of Juno Therapeutics (JUNO) -Susquehanna January 23, 2018 1:41 PM Investigational Data Presented at ASCO GI Evaluate ABRAXANE® Regimen for Patients with Locally Advanced Pancreatic CancerJanuary 19, 2018 5:30 PM Celgene's (CELG) Otezla Receives FDA Orphan Status for Treatment of Pediatric Patients with UCJanuary 18, 2018 3:04 PM Juno Therapeutics (JUNO) Sees Intra-Day Spike UpJanuary 18, 2018 11:31 AM